Lupin receives approval for Colesevelam Hydrochloride Tablets

19 Dec 2020 Evaluate

Lupin has received approval for its Colesevelam Hydrochloride Tablets, 625 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Welchol Tablets, 625 mg, of Daiichi Sankyo, Inc. Colesevelam Hydrochloride Tablets (RLD: Welchol) had an annual sales of approximately $159 million in the U.S. (IQVIA MAT September 2020).

Colesevelam Hydrochloride Tablets, 625 mg, are indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia and to reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

1659.15 20.05 (1.22%)
16-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1532.20
Dr. Reddys Lab 5820.00
Cipla 1423.85
Zydus Lifesciences 1008.15
Lupin 1659.15
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.